---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-341300"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2026-08-10T12:00:16+00:00"
generated_at: "2026-08-10T12:05:45.133425+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Heron Q2 revenue $37.7M (+1.3% YoY); withdraws FY2026 guidance on CINVANTI patent loss

## Summary
- Q2 net revenue $37.7M, up 1.3% YoY; Acute Care up 43.9%, Oncology down 15.9% (CINVANTI -9.7%, SUSTOL -77.5%).
- Withdrew FY2026 guidance after Delaware court ruling on CINVANTI patents; paused sales force expansion, considering strategic alternatives.
- Amended Hercules Capital credit facility: $13.5M principal reduction at execution, potential $4M more by Sept 15, 2026; covenants reset through 2027.
- Cash and investments $42.7M at quarter end; ZYNRELEF net revenue $11.1M (+35% YoY), APONVIE $4.2M (+74% YoY).

## SEC filing metadata
- accession: 0001193125-26-341300
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2026-08-10T12:00:16+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000119312526341300/0001193125-26-341300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000119312526341300/hrtx-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-341300
- JSON: https://secwatch.observer/filing/0001193125-26-341300.json
- Plain text: https://secwatch.observer/filing/0001193125-26-341300.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.